M&A Deal Summary

Takeda Acquires Shire

On May 8, 2018, Takeda acquired life science company Shire for 44.0B GBP

Acquisition Highlights
  • This is Takeda’s 10th transaction in the Life Science sector.
  • This is Takeda’s largest (disclosed) transaction.
  • This is Takeda’s 1st transaction in Ireland.

M&A Deal Summary
Date 2018-05-08
Target Shire
Sector Life Science
Buyer(s) Takeda
Deal Type Add-on Acquisition
Deal Value 44.0B GBP
Advisor(s) Citigroup Investment Banking
Goldman Sachs
Morgan Stanley (Financial)

Target

Shire

Dublin, Ireland
Shire plc is a global specialty biopharmaceutical company. Shire plc strive to develop best-in-class therapies across a core of rare disease areas including hematology, immunology, genetic diseases, neuroscience, and internal medicine with growing therapeutic areas in ophthalmics and oncology. Our diversified capabilities enable us to reach patients in more than 100 countries who are struggling to live their lives to the fullest.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Takeda

Tokyo, Japan
Category Company
Founded 1781
Sector Life Science
Employees47,347
Revenue 4.03T JPY (2023)
DESCRIPTION
Takeda's corporate headquarters in Tokyo, Japan.
Takeda's corporate headquarters in Tokyo, Japan.

Takeda is a global biopharmaceutical organization committed to improving the health and well-being of people worldwide. Takeda is dedicated to addressing unmet medical needs through the development of innovative and transformative therapies. The Company's diverse portfolio encompasses a wide range of therapeutic areas, including oncology, gastroenterology, rare diseases, neuroscience, and vaccines. Takeda was originally established in 1781 and is based in Tokyo, Japan.

DEAL STATS #
Overall 11 of 18
Sector (Life Science) 10 of 17
Type (Add-on Acquisition) 10 of 15
Country (Ireland) 1 of 1
Year (2018) 1 of 2
Size (of disclosed) 1 of 9
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2017-01-09 Ariad Pharmaceuticals

Cambridge, Massachusetts, United States

Ariad Pharmaceuticals, Inc. is an oncology company focused on transforming the lives of cancer patients with breakthrough medicines. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines.

Buy $5.2B
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2018-07-31 TiGenix N.V.

Leuven, Belgium

TiGenix N.V. is a European cell therapy company with a proprietary validated allogeneic expanded adipose-derived stem cell (eASC) platform technology for the treatment of autoimmune and inflammatory diseases, and a commercialized product. TiGenix was formed in 2000 and is based in Leuven, Belgium.

Buy -
Mergr

Product

Company

Legal